$ACHV
ACHIEVE LIFE SCIENCES, INC.

2016 Q4 Form 10-Q Financial Statement

#000156459016028946 Filed on November 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q4
Revenue $0.00 $0.00 $6.024M
YoY Change -100.0% -100.0% 6.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.300M $1.860M $2.920M
YoY Change -21.23% -40.58% 6.96%
% of Gross Profit
Research & Development $80.00K $69.00K $6.587M
YoY Change -98.79% -99.17% -33.14%
% of Gross Profit
Depreciation & Amortization $40.00K $50.00K $60.00K
YoY Change -33.33% -16.67% 20.0%
% of Gross Profit
Operating Expenses $80.00K $69.00K $6.587M
YoY Change -98.79% -99.4% -33.14%
Operating Profit
YoY Change
Interest Expense $40.00K $50.00K $30.00K
YoY Change 33.33% 150.0% 50.0%
% of Operating Profit
Other Income/Expense, Net -$4.000K -$7.000K $1.756M
YoY Change -100.23% -104.96% 78.64%
Pretax Income -$5.840M -$405.0K -$1.720M
YoY Change 239.53% -91.1% -69.72%
Income Tax
% Of Pretax Income
Net Earnings -$486.0K -$268.0K -$1.722M
YoY Change -71.78% -94.11% -69.69%
Net Earnings / Revenue -28.59%
Basic Earnings Per Share
Diluted Earnings Per Share -$584.0M -$369.0M -$172.0M
COMMON SHARES
Basic Shares Outstanding 30.02M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.25M $12.78M $20.94M
YoY Change -51.08% -80.6% -55.49%
Cash & Equivalents $15.00K $27.00K $67.00K
Short-Term Investments $10.23M $12.76M $20.88M
Other Short-Term Assets $1.000M $1.800M $14.00K
YoY Change 7042.86% 12.5% -97.19%
Inventory
Prepaid Expenses $3.000K
Receivables $478.0K $0.00
Other Receivables $0.00 $100.0K
Total Short-Term Assets $18.00K $34.30M $57.30M
YoY Change -99.97% -49.26% 2.76%
LONG-TERM ASSETS
Property, Plant & Equipment $300.0K $500.0K $600.0K
YoY Change -50.0% 31.58% 133.46%
Goodwill $1.034M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $300.0K $300.0K
YoY Change 0.0% 689.47% 9.89%
Total Long-Term Assets $3.789M $800.0K $902.0K
YoY Change 320.07% 25.0% 70.19%
TOTAL ASSETS
Total Short-Term Assets $18.00K $34.30M $57.30M
Total Long-Term Assets $3.789M $800.0K $902.0K
Total Assets $3.807M $35.10M $58.20M
YoY Change -93.46% -48.56% 3.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $95.00K $1.000M $1.300M
YoY Change -92.69% -43.79% 1705.56%
Accrued Expenses $6.000M $9.100M $11.90M
YoY Change -49.58% -26.61% -24.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0% -50.0%
Total Short-Term Liabilities $3.073M $10.59M $20.66M
YoY Change -85.13% -63.86% -6.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $100.0K $100.0K
YoY Change -100.0% 0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $100.0K $100.0K
YoY Change -100.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.073M $10.59M $20.66M
Total Long-Term Liabilities $0.00 $100.0K $100.0K
Total Liabilities $3.197M $10.66M $20.77M
YoY Change -84.61% -63.88% -6.58%
SHAREHOLDERS EQUITY
Retained Earnings -$2.062M -$191.1M -$176.8M
YoY Change -98.83% 10.54%
Common Stock $2.696M $212.9M $211.6M
YoY Change -98.73% 10.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $610.0K $24.42M $1.840M
YoY Change
Total Liabilities & Shareholders Equity $3.807M $35.07M $58.21M
YoY Change -93.46% -48.57% 3.41%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q4
OPERATING ACTIVITIES
Net Income -$486.0K -$268.0K -$1.722M
YoY Change -71.78% -94.11% -69.69%
Depreciation, Depletion And Amortization $40.00K $50.00K $60.00K
YoY Change -33.33% -16.67% 20.0%
Cash From Operating Activities -$6.980M -$7.260M -$10.68M
YoY Change -34.64% -15.97% 53.67%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 -$70.00K
YoY Change -85.71% -100.0%
Acquisitions
YoY Change
Other Investing Activities $10.42M $8.480M $2.570M
YoY Change 305.45% -175.24% -118.2%
Cash From Investing Activities $10.42M $8.480M $2.500M
YoY Change 316.8% -174.98% -117.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 10.00K
YoY Change -100.0% -100.0% -50.0%
NET CHANGE
Cash From Operating Activities -6.980M -7.260M -10.68M
Cash From Investing Activities 10.42M 8.480M 2.500M
Cash From Financing Activities 0.000 0.000 10.00K
Net Change In Cash 3.440M 1.220M -8.170M
YoY Change -142.11% -122.06% -61.19%
FREE CASH FLOW
Cash From Operating Activities -$6.980M -$7.260M -$10.68M
Capital Expenditures -$10.00K $0.00 -$70.00K
Free Cash Flow -$6.970M -$7.260M -$10.61M
YoY Change -34.31% -15.68% 52.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34310000
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Entity Registrant Name
EntityRegistrantName
ONCOGENEX PHARMACEUTICALS, INC.
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30020294
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1987000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
14000
CY2016Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
350000
CY2016Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
67000
CY2016Q3 us-gaap Liabilities
Liabilities
10655000
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10588000
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
30000
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
212843000
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-191097000
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2643000
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
24419000
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35074000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
OGXI
dei Entity Central Index Key
EntityCentralIndexKey
0000949858
CY2015Q3 us-gaap Reimbursement Revenue
ReimbursementRevenue
6737000
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30054287
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30020294
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
52000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
17577000
us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
34125000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1864000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3125000
CY2016Q3 ogxi Restructuring Costs Recovery
RestructuringCostsRecovery
-31000
ogxi Restructuring Costs Recovery
RestructuringCostsRecovery
392000
CY2016Q3 ogxi Gain On Reversal Of Lease Termination Liability
GainOnReversalOfLeaseTerminationLiability
1250000
ogxi Gain On Reversal Of Lease Termination Liability
GainOnReversalOfLeaseTerminationLiability
1250000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5040000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
17629000
us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
22942000
ogxi Expiration Of Operating Lease Agreement
ExpirationOfOperatingLeaseAgreement
2017-09
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2015Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
1003000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
34358000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
17659000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
194000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4581000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-22510000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
14580000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27897000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42477000
us-gaap Stock Issued1
StockIssued1
254000
CY2016Q3 us-gaap Reimbursement Revenue
ReimbursementRevenue
0
CY2016Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
350000
CY2016Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
32727000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.58
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2973955
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.78
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.86
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.25
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.35
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1105000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
755000
CY2016Q3 us-gaap Cash
Cash
1328000
CY2016Q3 ogxi Cash And Cash Equivalents Amortized Cost Basis
CashAndCashEquivalentsAmortizedCostBasis
19696000
CY2016Q3 ogxi Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax
CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2016Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
19700000
CY2016Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
12757000
CY2016Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2016Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
12755000
ogxi Maximum Maturity Period Of Cash And Cash Equivalents
MaximumMaturityPeriodOfCashAndCashEquivalents
P90D
ogxi Maximum Maturity Period Of Short Term Investments
MaximumMaturityPeriodOfShortTermInvestments
P1Y
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
207296
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
260676
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1479221
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1635250
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
16520
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
123996
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0151
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0174
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7188
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6231
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
-134000
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
712000
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1800000
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1800000
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7600000
ogxi Number Of Warrants Exercised
NumberOfWarrantsExercised
0
ogxi Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2015Q3 ogxi Expansion Of Rental Space Notice Provided
ExpansionOfRentalSpaceNoticeProvided
2245
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2015Q1 ogxi Additional Contingent Liability Early Termination Of Lease Agreement
AdditionalContingentLiabilityEarlyTerminationOfLeaseAgreement
1300000
CY2016Q3 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
ogxi Indemnification Expense
IndemnificationExpense
0
CY2016Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
11
CY2016Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.27
CY2016Q1 us-gaap Severance Costs1
SeveranceCosts1
400000

Files In Submission

Name View Source Status
0001564590-16-028946-index-headers.html Edgar Link pending
0001564590-16-028946-index.html Edgar Link pending
0001564590-16-028946.txt Edgar Link pending
0001564590-16-028946-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g20161109203840534963.jpg Edgar Link pending
ogxi-10q_20160930.htm Edgar Link pending
ogxi-20160930.xml Edgar Link completed
ogxi-20160930.xsd Edgar Link pending
ogxi-20160930_cal.xml Edgar Link unprocessable
ogxi-20160930_def.xml Edgar Link unprocessable
ogxi-20160930_lab.xml Edgar Link unprocessable
ogxi-20160930_pre.xml Edgar Link unprocessable
ogxi-ex101_342.htm Edgar Link pending
ogxi-ex311_10.htm Edgar Link pending
ogxi-ex312_6.htm Edgar Link pending
ogxi-ex321_7.htm Edgar Link pending
ogxi-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending